Current knowledge about Chronic fatigue syndrome / myalgic encephalomyelitis (CFS/ME) causes – summary

Monika Prylińska-Jaśkowiak¹, Marcin Kożuchowski¹

1. Department of Physiology of Physical Activity and Functional Anatomy, Faculty of Health Sciences, Collegium Medicum im. Ludwik Rydygier in Bydgoszcz, Nicolaus Copernicus University in Toruń

Abstract

Chronic Fatigue Syndrome (CFE) is a severe and disabling disease whose etiology has not yet been elucidated. This implies the lack of a specific biomarker for the diagnosis of PE, and no causal treatment. There are a number of diagnostic criteria that facilitate the diagnosis of PE, but it is still a diagnosis with exclusion. This chapter reviews the scientific literature systematically, summarizing the available knowledge about the probable etiology of Chronic Fatigue Syndrome. The current topic of the influence of SARS-Cov-2 virus infection on the development of symptoms of IPC was also taken into account in particular. A clear explanation of the etiology of PE is necessary for the further development of scientific knowledge about the Chronic Fatigue Syndrome.

Keywords: chronic fatigue syndrome, myalgic encephalomyelitis, CFS/ME causes, post-infection fatigue, post viral fatigue, post-covid fatigue
1. Introduction

The chronic fatigue syndrome (CFS) / myalgic encephalomyelitis (ME) is a severe and overwhelming disease, possibly involving the central nervous system, characterized primarily by constant, chronic fatigue, characteristically aggravating after undertaking physical or mental exertion and accompanying it with various additional symptoms. The topic of chronic fatigue syndrome is currently very topical, due to the ongoing pandemic of COVID-19 disease, caused by the SARS-Cov-2 virus, one of the complications of which is the development of chronic fatigue. The CFS etiology has not been confirmed yet, which implies difficulties in its diagnosis and treatment. In this publication, we would like to summarize the current scientific reports on the considered possible causes of the development of chronic fatigue syndrome.

2. Material and methods

This publication is based on a review of the scientific literature which was carried out by searching the Google Scholar and PubMed scientific databases. The following keywords were searched for: chronic fatigue syndrome, myalgic encephalomyelitis, CFS/ME causes, post-infection fatigue, post viral fatigue, post-covid fatigue. Based on the found publications, the current knowledge on the etiology and risk factors for the development of chronic fatigue syndrome was summarized.

3. Epidemiology of chronic fatigue syndrome

The occurrence of CFS is not precisely defined. Depending on the diagnostic criteria and the degree of their compliance, various sources indicate the frequency from 0.002% to 1% of the population [10]. We know, however, that due to the lack of an unambiguous definition of this disease and the lack of clear criteria for its diagnosis, the actual number of patients with IA is certainly much greater. The stereotypical image of a patient with PE is a white woman, aged 20-50 years, belonging to the white class, most often educated and ambitious ("yuppie flu") [11]. They suffer from severe chronic fatigue that reduces their quality of life (QOL) for months or years due to lack of specific treatment. CFS brings measurable economic losses to the society and health service [12].

4. The etiology of the chronic fatigue syndrome

The etiology and pathogenesis of chronic fatigue syndrome has not been clarified so far. Therefore, there is currently no specific test or marker that would allow a clear diagnosis of this disease [9, 13].

The high frequency of comorbidities with chronic fatigue syndrome suggests that its pathogenesis must involve the entire system, mechanism or multiple systems that influence each other, such as the cerebral-intestinal axis or the autonomic nervous system [12]. The research highlights the role of the immune system in the CFS pathogenesis [14]. Symptoms of CFS are often preceded by a flu-like viral infection, and infectious mononucleosis is a documented risk factor for the development of CFS [15]. Additionally, patients with CFS
have increased levels of pro-inflammatory cytokines, increased expression of T-lymphocyte activation markers - CD26 and CD38, and a decrease in NK cells [16, 17].

The high frequency of digestive system disorders, such as abdominal pain, changes in the rhythm of bowel movements, nausea, diarrhea or flatulence in those patients [5, 13]. Patients with chronic fatigue are significantly more likely to have a previous diagnosis of irritable bowel syndrome (IBS) in their medical history [18]. The frequent coexistence of chronic fatigue syndrome and irritable bowel syndrome may be associated with an increased level of pro-inflammatory cytokines activating the cerebral-intestinal axis [19]. In patients with diagnosed CFS and irritable bowel syndrome, higher levels of IL-6, IL-8, IL-1β and TNF-α have been proven [19]. Studies suggest that in patients with chronic fatigue there is a diffuse, low-grade chronic inflammation in the intestinal wall [20], which constantly activates the immune system and enhances the production of pro-inflammatory cytokines. An important link between the immune system and the brain is the hypothalamic-pituitary-adrenal axis [21]. Activation of the immune system and increased levels of pro-inflammatory cytokines, through this axis, increase the release of corticoliberin from the hypothalamus, which activates the hypothalamic-pituitary-adrenal axis, increases the level of stress hormones in the body [21, 22] and in response to the systemic stress response causes dysfunction and intestinal inflammation [20].

One of the postulated etiologies of chronic fatigue syndrome is the previously mentioned high level of pro-inflammatory cytokines and chronic diffuse intestinal inflammation [20]. There is a unique intestinal microflora in the human digestive tract, consisting of over 17 types of bacteria, with a total of about 500 different species of intestinal bacteria [13]. In a healthy organism, these bacteria remain in balance with each other and regulate a number of systemic reactions and processes in their host. The composition of the intestinal microflora, however, can be disturbed by a number of factors, including stress [23]. It has been proven that stress can reduce the size of the Bifidobacteria and Lactobacilli populations in the intestinal microflora [24]. Bifidobacteria have been shown to reduce intestinal lipopolysaccharide (LPS) levels in mice [25]. This results in the inhibition of LPS-dependent NK cell activation, which significantly reduces the level of pro-inflammatory cytokines and cyclooxygenase 2 (COX-2) [25]. Interestingly, stress (psychological or caused by physical exhaustion) is a well-proven risk factor for chronic fatigue syndrome [16].

Research shows that in people with IBS there are clear, measurable changes in the composition of the intestinal microflora, namely the level of Bifidobacteria is significantly reduced and the level of aerobic bacteria increases [26]. The determination of the composition of the intestinal microflora from stool samples of patients with chronic fatigue syndrome proved that Escherichia coli bacteria accounted for 92.3% of the aerobic microflora composition in the control group, compared to 49% in the group of CFS patients. On the other hand, aerobic bacteria of the genus Enterococcus and Streptococcus were overrepresented in the microflora of patients with IBS [27, 28]. Moreover, it has been shown that the greater the growth of Enterococcus bacteria in patients with PE, the more severe their cognitive impairment and neurological disorders such as anxiety, nervousness, memory impairment, easy forgetfulness and confusion [27]. The altered intestinal microflora may produce greater amounts of bacterial endotoxins, which may contribute to high levels of LPS in CFS patients [29].
The gastrointestinal tract, in order to prevent the development of uncontrolled, chronic inflammation, has developed a tight intestinal barrier, which is designed to limit the excessive growth of the intestinal microflora, inhibit the direct contact of the intestinal wall with bacteria and protect against the spread of bacteria from the intestinal lumen to adjacent tissues. Composed of a single layer of epithelial cells, the mucosal intestinal barrier is one of the most important

5. The influence of SARS-Cov-2 virus infection on the development of the chronic fatigue syndrome

For a long time, researchers have postulated viral infection as a trigger, a specific trigger factor that initiates a cascade of molecular and biochemical processes leading to the development of chronic fatigue syndrome in predisposed individuals, probably due to genetic factors [6]. There is scientific evidence confirming the development of CFS after infection with Epstein-Barr virus, enteroviruses, hepatotrophic viruses, Parvovirus B19, Ebola virus, Coxiella burnetii, polio virus [6]. It is postulated that viral infection can initiate a "cytokine storm" and a chain of chronic pro-inflammatory cytokine activation that can stimulate the immune system. The body's natural response to the immune system's fight against infection is "feeling sick", including weakness and fatigue, but also many other symptoms that are characteristic of CFS. Cytokine-activated pro-inflammatory cell initiation of the immune system and low-grade neuroinflammation, with microglia activation, may underlie CFS. [6]

COVID-19 is a viral infection caused by the SARS-CoV-2 virus that primarily affects the respiratory system, with initial symptoms often including shortness of breath and fever. Currently, less than 190 million confirmed cases of infections have been reported in the world so far, and millions of infected people have died. A significant proportion of COVID-19 survivors experience long-term health consequences, including development of chronic fatigue.

In the acute phase of COVID-19 disease, multi-organ damage, especially of the lungs, heart and kidneys, may occur, which may itself lead to the development of chronic complications. Therefore, in some people with persistent, debilitating fatigue after COVID-19, documented damage to these organs may be a sufficient explanation for their fatigue [45]. However, many cases of chronic fatigue develop in convalescents who have not suffered permanent damage to their internal organs. follows acute infections not known to cause permanent damage to the heart, lungs, or kidneys - and in people without PTSD or depression. In a typical case of CFS, in particular, the cause of the "infection-like" disease most often appears to be a transient infection or a primary infection that becomes permanent and usually does not cause chronic multiorgan dysfunction [45]. The pathogenesis of the development of chronic fatigue after COVID-19 may probably be very similar to the previously described cytokine cascade after viral infection. The final etiology of CFS requires further research and a final explanation. Perversely, it can be said that one of the good effects of a pandemic may be the increased awareness of the disease, which is chronic fatigue syndrome. Until now, this disease was present mainly in the scientific world, while among clinicians and people who have daily contact with such patients, the knowledge about CFS was very low.
7. Summary

In conclusion, a review of the currently available studies attempting to elucidate the etiology of chronic fatigue syndrome shows that the etiology may be complex and multifactorial. The most probable theories seem to be the post-infectious cytokine cascade, disturbances in the composition of the intestinal microflora and intestinal barrier dysfunction, disturbances on the cerebral-intestinal and cerebral-adrenal axis, the persistence of a low level of immune system stimulation and chronic oxidative stress in the body. Further research in the field of elucidating the etiology and pathogenesis of CFS is necessary. This will enable in the future the development of a biochemical marker that will make it possible to unequivocally make the diagnosis of CFS, and will also contribute to the development of an effective method of causal treatment of this disease.

References

1. Holmes G. P., Kaplan J. E., Gantz N. M., Komaroff A. L., Schonberger L. B., Straus S. E., Tosato G., Chronic fatigue syndrome: a working case definition, Annals of internal medicine, 108(3), (1988), 387-389.
2. Fukuda K., Straus S. E., Hickie I., Sharpe M. C., Dobbins J. G., Komaroff A., The chronic fatigue syndrome: a comprehensive approach to its definition and study, Annals of internal medicine, 121(12), (1994), 953-959.
3. Kurowski M., Kuna P., Zespół przewlekłego zmęczenia, Alergia Astma Immunologia 1997; 2(4): 223-228
4. Carruthers B. M., van de Sande M. I., De Meirleir K. L., Klimas N. G., Broderick G., Mitchell T., Bateman L., Myalgic encephalomyelitis: international consensus criteria, Journal of internal medicine, 270(4), (2011), 327-338.
5. Komaroff A. L., Fagioli L. R., Geiger A. M., Doolittle T. H., Lee J., Kornish R. J., Guerriero R. T., An examination of the working case definition of chronic fatigue syndrome, The American journal of medicine, 100(1), (1996), 56-64.
6. Shepherd D. C., Chaudhuri A., ME/CFS/PVFS: An exploration of the key clinical issues, ME Association, (2019).
7. Jason L. A., Sunnquist M., Brown A., Evans M., Newton J. L., Are Myalgic Encephalomyelitis and chronic fatigue syndrome different illnesses? A preliminary analysis., Journal of health psychology, 21(1), (2016), 3-15.
[8] Cotler J., Holtzman C., Dudun C., Jason L. A., A brief questionnaire to assess post-exertional malaise, Diagnostics, 8(3), (2018), 66.
[9] Campagnolo N., Johnston S., Collatz A., Staines D., Marshall-Gradisnik S., Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review, Journal of human nutrition and dietetics, 30(3), (2017), 247-259.
10. Straus S. E., Komaroff A. L., Wedner H. J., Chronic fatigue syndrome: point and counterpoint, Journal of Infectious Diseases, 170(1), (1994), 1-6.
11. Gunn W. J., Connell D. B., Randall B., *Epidemiology of chronic fatigue syndrome: the Centers for Disease Control Study*, In Ciba Foundation Symposium 173-Chronic Fatigue Syndrome: Chronic Fatigue Syndrome: Ciba Foundation Symposium 173, (2007), 83-101

12. Bombardier C. H., Buchwal, D., *Chronic fatigue, chronic fatigue syndrome, and fibromyalgia: disability and health-care use*, Medical Care, (1996), 924-930.

13. Lakhan S. E., Kirchgessner, A., *Gut inflammation in chronic fatigue syndrome*, Nutrition & metabolism, 7(1), (2010), 79.

14. Fletcher M. A., Zeng X. R., Barnes Z., Levis S., Klimas N. G., *Plasma cytokines in women with chronic fatigue syndrome*, Journal of translational medicine, 7(1), (2009), 96.

15. White P. D., Thomas J. M., Amess J., Crawford D. H., Grover S. A., Kangro H. O., Clare A. W., *Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever*, The British Journal of Psychiatry, 173(6), (1998), 475-481.

16. Maes M., Mihaylova I., Leunis J. C., *Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability*, Journal of affective disorders, 99(1-3), (2007), 237-240.

17. Lorusso L., Mikhailova S. V., Capelli E., Ferrari D., Ngonga G. K., Ricevuti G., *Immunological aspects of chronic fatigue syndrome*, Autoimmunity reviews, 8(4), (2009), 287-291.

18. Aaron L. A., Burke M. M., Buchwald D., *Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder*, Archives of internal medicine, 160(2), (2000), 221-227.

19. Scully P., McKernan D. P., Keohane J., Groeger D., Shanahan F., Dinan, T. G., Quigley E. M., *Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity*, The American journal of gastroenterology, 105(10), (2010), 2235.

20. Clarke G., Quigley E. M., Cryan J. F., Dinan T. G., *Irritable bowel syndrome: towards biomarker identification*, Trends in molecular medicine, 15(10), (2009), 478-489.

21. Gaab J., Rohleder N., Heitz V., Engert V., Schad T., Schürmeyer T. H., Ehlert U., *Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome*, Psychoneuroendocrinology, 30(2), (2005), 188-198.

22. Raber J., Sorg O., Horn T. F. W., Yu N., Koob G. F., Campbell I. L., Bloom F. E., *Inflammatory cytokines: putative regulators of neuronal and neuro-endocrine function*, Brain research reviews, 26(2-3), (1998), 320-326.

23. Jiménez M. B., *Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last*, Revista Espanola de Enfermedades Digestivas, 101, (2009), 553-564.

24. Bailey M. T., Lubach G. R., Coe C. L., *Prenatal stress alters bacterial colonization of the gut in infant monkeys*, Journal of pediatric gastroenterology and nutrition, 38(4), (2004), 414-421.
25. Riedel C. U., Foata F., Philipp, D., Adolfsson O., Eikmanns B. J., Blum S., Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-κB activation, World journal of gastroenterology: WJG, 12(23), (2006), 3729.

26. Logan A. C., Rao A. V., Irani D., Chronic fatigue syndrome: lactic acid bacteria may be of therapeutic value, Medical hypotheses, 60(6), (2003), 915-923.

27. Butt H. L., Dunstan R. H., McGregor N. R., Roberts T. K., Bacterial colonos in patients with persistent fatigue, In Proceedings of the AHMF international clinical and scientific conference, (2001), 1-2.

28. Sheedy J. R., Wettenhall R. E., Scanlon D., Gooley P. R., Lewis D. P., Mcegro, N., De Meirleir K. L., Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome, In vivo, 23(4), (2009), 621-628.

29. Cani P. D., Possemiers S., Van de Wiele T., Guiot Y., Everard A., Rottier O., Muccioli G. G., Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability, (2009).

30. Swidsinski A., Ladhoff A., Pernthaler A., Swidsinski S., Loening–Baucke V., Ortner M., Lochs H., Mucosal flora in inflammatory bowel disease, Gastroenterology, 122(1), (2002), 44-54.

31. Zhou Q., Zhang B., Verne G. N. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146(1-2), (2009), 41-46.

32. Lee K. J., Tack J., Altered intestinal microflora in irritable bowel syndrome, Neurogastroenterology & Motility, 22(5), (2010), 493-498.

33. Törnblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123(6), (2002), 1972-1979.

34. De Giorgio R., Camilleri M., Human enteric neuropathies: morphology and molecular pathology, Neurogastroenterology & Motility, 16(5), (2004), 515-531.

35. Sido B., Hack V., Hochlehnert A., Lipps H., Herfarth C., Dröge W., Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease, Gut, 42(4), (1998), 485-492.

36. Maes M., Twisk F. N., Chronic fatigue syndrome: Harvey and Wessely's (bio) psychosocial model versus a bio (psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways, BMC medicine, 8(1), (2010), 35.

37. Wagner F., Asfar P., Calzia E., Radermacher P., Szabó C., Bench-to-bedside review: Hydrogen sulfide—the third gaseous transmitter: applications for critical care, Critical care, 13(3), (2009), 213.

38. Reiffenstein R. J., Hulber W. C., Roth S. H., Toxicology of hydrogen sulfide, Annual review of pharmacology and toxicology, 32(1), (1992), 109-134.

39. Fiorucci S., Distrutti E., Cirino G., Wallace J. L., The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver, Gastroenterology, 131(1), (2006), 259-271.
40. Schicho R., Krueger D., Zeller F., Von Weyhern C. W. H., Frieling T., KimuranH., Schemann M., *Hydrogen sulfide is a novel prosecretory neuromodulator in the Guinea-pig and human colon*, Gastroenterology, 131(5), (2006), 1542-1552.

41. Myhill S., Booth N. E., McLaren-Howard J., *Chronic fatigue syndrome and mitochondrial dysfunction*, International journal of clinical and experimental medicine, 2(1), (2009), 1.

42. Sheedy J. R., Wettenhall R. E., Scanlon D., Gooley P. R., Lewis D. P., McGregor N., De Meirleir K. L., *Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome*, In vivo, 23(4), (2009), 621-628.

43. Jammes Y., Steinberg, J. G., Mambrini O., Bregeon F., Delliaux S., *Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise*, Journal of internal medicine, 257(3), (2005), 299-310.

44. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E., *Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder*, Neuro endocrinology letters, 30(4), (2009), 470-476.

45. Komaroff A. L., Bateman L., *Will COVID-19 Lead to Myalgic encephalomyelitis/chronic fatigue syndrome?*, Frontiers in Medicine, 7, (2021), 1132.